Substitution of anticonvulsant drugs

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 449-457

  Steinhoff, Bernhard J ^a   Runge, Uwe ^b   Witte, Otto W ^c   Stefan, Hermann ^d   Hufnagel, Andreas ^e   Mayer, Thomas ^f   Krämer, Günter ^g  

^a Epilepsy Center Kork   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e Neurocenter   (Germany)

^f Epilepsy Center Kleinwachau   (Germany)

^g SWISS EPILEPSY CENTER   (Switzerland)

Author keywords

Anticonvulsant drugs; Epilepsy; Generic drugs

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ANXIETY DISORDER; AREA UNDER THE CURVE; ATAXIA; BIOEQUIVALENCE; DIPLOPIA; DIZZINESS; DRUG SUBSTITUTION; EPILEPSY; FALLING; HEALTH CARE COST; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; MEDICAL DECISION MAKING; MOOD DISORDER; NAUSEA; NYSTAGMUS; PATIENT CARE; PHARMACIST; PHARMACY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; VERTIGO;

EID: 77949445751     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s5366     Document Type: Review

References (57)

1. Pharmaceutical Forum. Second progress report, 26 June 2007. [cited 2008 Nov 15]. Available from: http://ec.europa.eu/enterprise/phabiocom/docs/pf- 20070626-progr-report.pdf.
2. Nashef L, Fish DR, Garner S, Sander JW, Shorvon SD. Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and learning difficulty. Epilepsia. 1995;36:1187-1194.
3. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006;15:165-176.
4. Trimble MR. Generic prescribing. Hum Psychopharmacol. 1987;2:1-2.
5. Welty TE, Pickering PR, Hale BC, Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother. 1992;26:775-777.
6. Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovic J, Baker R. Clinical guidelines and evidence review for the epilepsies: Diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Practitioners; 2004.
7. American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1990;40:1641-1643.
8. Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology. 2007;68:1249-1250.
9. MPA (Läkemedelsverket). Substitutable medical products. Uppsala: Läkemedelsverket; 2006.
10. MPA (Läkemedelsverket). Neurontin and gabapentin nycomed - why aren't they interchangeable? Uppsala: Läkemedelsverket; 2004.
11. National Agency for Medicines (Laakelaitos). The National Agency for Medicines' updated (November 2005) principles for the preparation of interchangeable drugs that are authorized for sale. Helsinki: Laakelaitos; 2005.
12. Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia. 2006;47(Suppl 5):16-20.
13. Lamy PP. Generic equivalents: issues and concerns. J Clin Pharmacol. 1986;26:309-316.
14. Schmidt D, Loscher W. Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurol Scand. 2005;111:291-300.
15. Feely M, Crawford P, Kramer G, Guberman A. Risk management in epilepsy: generic substitution and continuity of supply. Eur J Hosp Pharm Sci. 2005;11:83-87.
16. EUCARE. European White Paper on Epilepsy. Epilepsia. 2003;44(Suppl 6):1-88.
17. National Society for Epilepsy. Epilepsy. Getting around: driving and travel. Chalfont St Peter: National Society for Epilepsy; 2006.
18. Mayer T, May TW, Altenmüller DM, Sandmann M, Wolf P. Clinical problems with generic antiepileptic drugs. Clin Invest Drug. 1999;18:17-26.
19. Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology. 1993;43:2696-2697.
20. Di Bonaventura C, Fattouch J, Fabbrini G, Manfredi M, Prencipe M, Giallonardo TA. Switching from branded to generic antiepileptic drugs as a confounding factor and unpredictable diagnostic pitfall in epilepsy management. Epileptic Disord. 2007;9:465-466.
21. Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd JC. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology. 2004;63:1494-1496.
22. Nielsen KA, Dahl M, Tommerup E, Wolf P. Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav. 2008;13:127-130.
23. Schmidt D. Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy. Epilepsy Res. 2002;52:61-69.
24. Zachry WM, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia. 2009;50(3):493-500.
25. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48:464-469.
26. Makus KG, McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther. 2007;29:334-341.
27. LeLorier J, Duh MS, Paradis PE, et al. The risks of multiple-generic substitution of antiepileptic drugs: the case of topiramate. Poster #PND46 presented at ISPOR 13th Annual International Meeting; 2008 May 3-7; Toronto, ON, Canada.
28. Meyer MC, Straughn AB, Mhatre RM, Shah VP, Williams RL, Lesko LJ. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res. 1998;15:1787-1791.
29. Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR, Shah VP. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res. 1992;9:1612-1616.
30. Silpakit O, Amornpichetkoon M, Kaojarern S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann Pharmacother. 1997;31:548-552.
31. Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J Neurol Neurosurg Psychiatry. 1992;55:688-691.
32. Hartley R, Aleksandrowicz J, Ng PC, McLain B, Bowmer CJ, Forsythe WI. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability? Br J Clin Pract. 1990;44:270-273.
33. MacDonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology. 1987; 37:1885.
34. Wyllie E, Pippenger CE, Rothner AD. Increased seizure frequency with generic primidone. JAMA. 1987;258:1216-1217.
35. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. 2008;71:525-530.
36. Crawford P, Hall WW, Chappell B, Collings J, Stewart A. Generic prescribing for epilepsy. Is it safe? Seizure. 1996;5:1-5.
37. Guberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci. 2000;27:37-43.
38. McAuley JW, Chen AY, Elliott JO, Shneker BF. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav. 2009;14(1):113-117.
39. Haskins LS, Tomaszewski KJ, Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav. 2005;7:98-105.
40. Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ. Generic substitution in the treatment of epilepsy: Patient and physician perceptions. Epilepsy Behav. 2008;13(4):693-699.
41. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 2004;5:995-998.
42. Biraben A, De TB, Semah F, Rouaud T. [Use of generic anti-epilepsy drugs in France: survey of neurologists and review of the literature]. Rev Neurol (Paris). 2007;163:455-461.
43. Krämer G, Steinhoff BJ, Feucht M, Pfäfflin M, May TW. Experiences with generic drugs in epilepsy patients. Results of an internet-based questionnaire study in Germany, Austria, and Switzerland. Akt Neurol. 2006;33:431-438.
44. Wilner AN. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav. 2002;3:522-525.
45. LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology. 2008;70:2179-2186.
46. Epilepsy Action. Position statement - consistency of supply. Leeds: British Epilepsy Association; 2005.
47. AFSSAPS. Press release. Substitution des médicaments antiépileptiques. Paris: Agence française de sécurité sanitaire des produits de santé; 2008.
48. Krämer G, Dennig D, Schmidt D, et al. Generics in antiepileptic drug therapy: what has to be considered? Akt Neurol. 2005;32:275-278.
49. LFCE. Recommendations on the use of generics for the treatment of epilepsy. Bron: French Chapter of the International League Against Epilepsy; 2008.
50. Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsy in adults. A national guideline. Edinburgh: Royal College of Physicians; 2003.
51. Brainwave. Submission to the Oireachtas Joint Committee on Health and Children in respect of the proposed substitution by generic AEDs (anti-epileptic drugs) of branded AEDs. Epilepsy News. 2008;37:4-5.
52. Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol. 2007;6:465-468.
53. Kitson A, Shorvon S. Clinical Standards Advisory Group. Services for patients with epilepsy. London: Department of Health; 2000.
54. Shorvon SD. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia. 1996;37(Suppl 2):S1-S3.
55. Hanna NJ, Black M, Sander JW, et al. The National Sentinel Clinical Audit of Epilepsy-Related Death. Epilepsy - death in the shadows. Norwich: HMSO; 2002.
56. Anon. Epilepsy: safety, excess mortality and sudden death. Epilepsia. 2003;44(Suppl 6):19-20.
57. Tomson T, Walczak T, Sillanpaa M, Sander JW. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia. 2005;46(Suppl 11):54-61.